104 related articles for article (PubMed ID: 1356015)
1. The role of erbB-2 and its ligands in growth control of malignant breast epithelium.
Lupu R; Dickson RB; Lippman ME
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):229-36. PubMed ID: 1356015
[TBL] [Abstract][Full Text] [Related]
2. The role of erbB-2 and its ligands in growth control of malignant breast epithelium.
Lupu R; Dickson RB; Lippman ME
Princess Takamatsu Symp; 1991; 22():49-60. PubMed ID: 1688228
[TBL] [Abstract][Full Text] [Related]
3. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses.
Lupu R; Colomer R; Kannan B; Lippman ME
Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2287-91. PubMed ID: 1347947
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
8. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y
Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672
[TBL] [Abstract][Full Text] [Related]
9. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL
Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001
[TBL] [Abstract][Full Text] [Related]
10. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
[TBL] [Abstract][Full Text] [Related]
11. Modulation of EGF receptor protooncogene expression by growth factors and hormones in human breast carcinoma cells.
Fernandez-Pol JA
Crit Rev Oncog; 1991; 2(2):173-85. PubMed ID: 1677274
[TBL] [Abstract][Full Text] [Related]
12. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
13. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran D; Tzahar E; Beerli RR; Chen X; Graus-Porta D; Ratzkin BJ; Seger R; Hynes NE; Yarden Y
EMBO J; 1996 Jan; 15(2):254-64. PubMed ID: 8617201
[TBL] [Abstract][Full Text] [Related]
14. Biology of HER2 and its importance in breast cancer.
Yarden Y
Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
16. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.
Komurasaki T; Toyoda H; Uchida D; Morimoto S
Oncogene; 1997 Dec; 15(23):2841-8. PubMed ID: 9419975
[TBL] [Abstract][Full Text] [Related]
17. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.
Langton BC; Crenshaw MC; Chao LA; Stuart SG; Akita RW; Jackson JE
Cancer Res; 1991 May; 51(10):2593-8. PubMed ID: 1673637
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells.
Marth C; Lang T; Cronauer MV; Doppler W; Zeimet AG; Bachmair F; Ullrich A; Daxenbichler G
Int J Cancer; 1992 Sep; 52(2):311-6. PubMed ID: 1355758
[TBL] [Abstract][Full Text] [Related]
19. Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells.
Noguchi M; Murakami M; Bennett W; Lupu R; Hui F; Harris CC; Gerwin BI
Cancer Res; 1993 May; 53(9):2035-43. PubMed ID: 7683250
[TBL] [Abstract][Full Text] [Related]
20. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
